+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acromegaly - Pipeline Review, H2 2019

  • ID: 4861732
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 102 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amryt Pharma Plc
  • Camurus AB
  • DexTech Medical AB
  • GlyTech Inc
  • Ionis Pharmaceuticals Inc
  • leon-nanodrugs GmbH
  • MORE
Acromegaly - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2019, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 6, 5 and 4 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amryt Pharma Plc
  • Camurus AB
  • DexTech Medical AB
  • GlyTech Inc
  • Ionis Pharmaceuticals Inc
  • leon-nanodrugs GmbH
  • MORE
Introduction
Acromegaly - Overview
Acromegaly - Therapeutics Development
Acromegaly - Therapeutics Assessment
Acromegaly - Companies Involved in Therapeutics Development
Acromegaly - Drug Profiles
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Acromegaly, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acromegaly - Pipeline by Amryt Pharma Plc, H2 2019
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2019
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2019
Acromegaly - Pipeline by Ascil Proyectos SL, H2 2019
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2019
Acromegaly - Pipeline by Camurus AB, H2 2019
Acromegaly - Pipeline by Chiasma Inc, H2 2019
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2019
Acromegaly - Pipeline by DexTech Medical AB, H2 2019
Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2019
Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2019
Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
Acromegaly - Pipeline by GlyTech Inc, H2 2019
Acromegaly - Pipeline by GP Pharm SA, H2 2019
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Acromegaly - Pipeline by Italfarmaco SpA, H2 2019
Acromegaly - Pipeline by leon-nanodrugs GmbH, H2 2019
Acromegaly - Pipeline by Midatech Pharma Plc, H2 2019
Acromegaly - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Acromegaly - Pipeline by ProLynx LLC, H2 2019
Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2019
Acromegaly - Dormant Projects, H2 2019
Acromegaly - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Acromegaly, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amryt Pharma Plc
  • Antisense Therapeutics Ltd
  • Aquestive Therapeutics Inc
  • Ascil Proyectos SL
  • Auritec Pharmaceuticals Inc
  • Camurus AB
  • Chiasma Inc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • Enesi Pharma Ltd
  • Foresee Pharmaceuticals Co Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • GlyTech Inc
  • GP Pharm SA
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • leon-nanodrugs GmbH
  • Midatech Pharma Plc
  • Ono Pharmaceutical Co Ltd
  • ProLynx LLC
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll